menu
    • menu

    Company profile for Symbiotica

    Default Key Product, Service and Excipients
    News
    Novo Nordisk receives FDA warning linked to US inspection in 2025

    11 Mar 2026

    // REUTERS

    FDA approves leucovorin for Rare Genetic Disorder Causing Autism

    11 Mar 2026

    // REUTERS

    Lilly pledges $500M to South Korea biopharma industry

    11 Mar 2026

    // FIERCE BIOTECH

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    BePharma

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/fda-approvals-drop-8-in-2025-with-fewer-blockbusters-brinsupri-rhapsido-make-it-to-first-in-class-list

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Symbiotica is a Malaysia-based manufacturer of high-quality Active Pharmaceutical Ingredients (APIs), specialising in steroidal, hormonal, and niche non-steroidal compounds for global pharmaceutical markets. With over 20 years of industry expertise, we serve 250+ clients across 80+ countries through GMP-certified facilities. Our tailored API solutions are driven by strong R&D, stringent quality systems, and regulatory compliance, delivering reliable and innovative pharmaceutical solutions worldwide. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SymbioticaMalaysia Flag
    Country
    Country
    Malaysia
    Address
    Address
    3-9-B, NB Plaza, 3000, Jalan Baru, 13700, Perai, Pulau Pinang
    Telephone
    Telephone
    Client Email
    Email
    symbioti@symbiotica.com.my
    Client Website
    Website
    http://www.symbiotica.com.my
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/symbiotica-party-content-13740.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 15546

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Symbiotica and get a quotation

    Symbiotica is a supplier offers 50 products (APIs, Excipients or Intermediates).

    Find a price of Mometasone Furoate bulk with DMF, CEP, JDMF offered by Symbiotica

    Find a price of Betamethasone Dipropionate bulk with DMF, CEP offered by Symbiotica

    Find a price of Clobetasol Propionate bulk with DMF, CEP offered by Symbiotica

    Find a price of Dexamethasone Sodium Phosphate bulk with DMF, CEP offered by Symbiotica

    Find a price of Exemestane bulk with DMF, CEP offered by Symbiotica

    Find a price of Betamethasone Valerate bulk with CEP offered by Symbiotica

    Find a price of Betamethasone Sodium Phosphate bulk with CEP offered by Symbiotica

    Find a price of Clobetasone Butyrate bulk with JDMF offered by Symbiotica

    Find a price of Halobetasol bulk with DMF offered by Symbiotica

    Find a price of Hydrocortisone Valerate bulk with DMF offered by Symbiotica

    Find a price of Mometasone Furoate bulk with CEP offered by Symbiotica

    Find a price of Prednisolone Acetate bulk with CEP offered by Symbiotica

    Find a price of Testosterone Propionate bulk with CEP offered by Symbiotica

    Find a price of Tibolone bulk with CEP offered by Symbiotica

    Find a price of Agomelatine bulk offered by Symbiotica

    Find a price of Beclomethasone Dipropionate bulk offered by Symbiotica

    Find a price of Betamethasone bulk offered by Symbiotica

    Find a price of Betamethasone Acetate bulk offered by Symbiotica

    Find a price of Budesonide bulk offered by Symbiotica

    Find a price of Carvedilol bulk offered by Symbiotica

    Find a price of Clostebol Acetate bulk offered by Symbiotica

    Find a price of Deflazacort bulk offered by Symbiotica

    Find a price of Desonide bulk offered by Symbiotica

    Find a price of Desoximetasone bulk offered by Symbiotica

    Find a price of Dexamethasone bulk offered by Symbiotica

    Find a price of Dexamethasone Sodium Phosphate bulk offered by Symbiotica

    Find a price of Diflorasone bulk offered by Symbiotica

    Find a price of Drospirenone bulk offered by Symbiotica

    Find a price of Ezetimibe bulk offered by Symbiotica

    Find a price of Fluocinonide bulk offered by Symbiotica

    Find a price of Hydrocortisone bulk offered by Symbiotica

    Find a price of Hydrocortisone Butyrate bulk offered by Symbiotica

    Find a price of Hydrocortisone Valerate bulk offered by Symbiotica

    Find a price of Hydroxyzine Hydrochloride bulk offered by Symbiotica

    Find a price of Ketorolac Trometamol bulk offered by Symbiotica

    Find a price of Levocetirizine Dihydrochloride bulk offered by Symbiotica

    Find a price of Linezolid bulk offered by Symbiotica

    Find a price of Methylprednisolone Aceponate bulk offered by Symbiotica

    Find a price of Methylprednisolone Acetate bulk offered by Symbiotica

    Find a price of Methylprednisolone Hemisuccinate bulk offered by Symbiotica

    Find a price of Mosapride Citrate bulk offered by Symbiotica

    Find a price of Pinaverium Bromide bulk offered by Symbiotica

    Find a price of Prednicarbate bulk offered by Symbiotica

    Find a price of Prednisolone Sodium Phosphate bulk offered by Symbiotica

    Find a price of Prucalopride Succinate bulk offered by Symbiotica

    Find a price of Tofisopam bulk offered by Symbiotica

    Find a price of Triamcinolone Acetonide bulk offered by Symbiotica

    Find a price of Triamcinolone Diacetate bulk offered by Symbiotica

    Find a price of Triamcinolone Hexacetonide bulk offered by Symbiotica

    Find a price of Trilostane bulk offered by Symbiotica

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search